MGRX (Mangoceuticals) LT-Debt-to-Total-Asset: 0.02 (As of Mar. 2026)


MGRX Mangoceuticals Inc MGRX
23 GF Score
Price $0.47
GF Value $0.32
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Mangoceuticals LT-Debt-to-Total-Asset?

Mangoceuticals MGRX +11.90% 23 LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus rates MGRX with a GF Score™ of 23/100 and a GF Value™ of $0.32 (Significantly Overvalued). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Mangoceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.02.

Mangoceuticals's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.02). It may suggest that Mangoceuticals is progressively becoming more dependent on debt to grow their business.

Mangoceuticals  (NAS:MGRX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mangoceuticals LT-Debt-to-Total-Asset Related Terms

Mangoceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Mangoceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangoceuticals LT-Debt-to-Total-Asset Chart

Mangoceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.00 0.13 0.06 0.00 0.00

Mangoceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.02
MGRX
23GF Score
Mangoceuticals Inc MGRX
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangoceuticals LT-Debt-to-Total-Asset Calculation

Mangoceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0/16.09
=0.00

Mangoceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0.237/14.449
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.02 mean?
Mangoceuticals (MGRX) has a LT-Debt-to-Total-Asset of 0.02 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Mangoceuticals and its competitors.
Is Mangoceuticals' LT-Debt-to-Total-Asset too high?
Mangoceuticals' current LT-Debt-to-Total-Asset is 0.02. Overall, Mangoceuticals has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mangoceuticals' LT-Debt-to-Total-Asset compare to WLSS and ACON?
Mangoceuticals' LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?
A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Mangoceuticals and its competitors. Mangoceuticals's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangoceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mangoceuticals (MGRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $0.47 — trading 45.3% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.02. Mangoceuticals' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Mangoceuticals (MGRX), the current LT-Debt-to-Total-Asset is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangoceuticals (MGRX) Overvalued in 2026?

Based on GuruFocus' analysis, Mangoceuticals stock appears to be overvalued. The current stock price of $0.47 is trading 45.3% above its estimated GF Value™ of $0.32. GuruFocus considers Mangoceuticals to be Significantly Overvalued.

Key valuation signals for MGRX:

  • LT-Debt-to-Total-Asset: 0.02
  • GF Value™: $0.32 vs. price of $0.47 (45.3% above fair value)
  • GF Score™: 23/100 with 2 warning signs

No single metric tells the full story. See the MGRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangoceuticals Business Description

Address 17130 Dallas Parkway, Suite 240, Dallas, TX, USA, 75248
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
23GF Score

Get the complete analysis for MGRX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price
$0.32
GF Value